$JNJ will bounce - Dip opportunity

I love JNJ long and believe that they are going to be fine with the recent COVID-related dip.

Their vaccine could do more damage than AstraZeneca's and governments will still buy it in order to herd the sheep.

You need to understand that JNJ is so much more than a vaccine company.

Expect this stock to go back up to the $167 level, as well as breaking the $170 level as well.

A great swing trade (buy covid dips), and I also love this long-term.

Lots of money to be made here!


*Not a financial advisor.

**Don't judge me on my winners. Judge me on my losers, because there are so few.
buythedipCoronavirus (COVID-19)JNJTrend Analysisvaccine

Clause de non-responsabilité